Finally, I explored therapeutic options targeting iron metabolism or inflammasome signaling, such as iron chelation, hepcidin antagonism, and interleukin-1 beta (IL-1β) blockade, as potential interventions to treat adipose tissue dysfunction in obesity and T2D. Here, HAMP is linked to type 2 diabetes mellitus.